In hematological malignancy patients without an available HLAidentical sibling or matched unrelated donor, the use of T-cell replete related donor haploidentical hematopoietic cell transplantation (haplo-HCT), using post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis, is rapidly increasing. 1, 2 PT-Cy mitigates the risk of GvHD by targeting alloreactive donor T cells rapidly proliferating early after an HCT, whilst sparing regulatory T cells, and nondividing hematopoietic stem and progenitor cells. 3 Viral reactivations and infections are an important cause of morbidity and mortality after allogeneic HCT. They appear to be more common after T-cell depleted compared with T-cell replete haplo-HCT. 4 The relative resistance of non-alloreactive donor memory T cells (responsible for cellular immunity against viral pathogens) to PT-Cy 5 could mitigate the risk of viral infections following T-cell replete haplo-HCT. However, there is a paucity of published data about the incidence, and severity of viral reactivations and infections following PT-Cy-based haplo-HCT. 6 Moreover, the impact of conditioning regimen intensity on the risk of viral infectious complications after PT-Cy-based haplo-HCT is not known. In the current single-center study, we analyze the incidence of viral infectious complications following T-cell replete haplo-HCT, relative to the intensity of conditioning regimens.
We retrospectively evaluated the incidence of viral reactivations and infections in the first 180 days after transplantation. All adult patients (age ⩾ 18 years) receiving a haplo-HCT (n = 43) at our transplant center between 2012 and 2015 were eligible for this study. Patient characteristics are described in Table 1 . GvHD prophylaxis in all patients consisted of PT-Cy, tacrolimus and mycophenolate mofetil. All patients received antiviral prophylaxis with acyclovir 800 mg twice daily. Quantitative nucleic acid amplified tests (NAAT) were performed on peripheral blood specimens to monitor for CMV (weekly), EBV (every other week) and adenoviral reactivation (every other week). Human herpes virus-6 (HHV-6) NAAT was performed as clinically indicated. BK polyoma (BK) virus NAAT in urine was performed on patients with signs or symptoms suspicious for cystitis. Upper respiratory tract viral swabs or viral testing on lower respiratory tract specimens (obtained via broncho alveolar lavage) were carried out for patients presenting with signs or symptoms of respiratory tract infections. All invasive viral infections requiring treatment, and/or hospitalization and CMV reactivations that required preemptive antiviral therapy were considered in our analysis. The median follow-up of survivors is 384 (range 94-1339) days. The median time to neutrophil and platelet engraftment was 17 days (range 12-51) and 25 days (range 11-108), respectively. The median T-cell and myeloid cell chimerism at day +30 on lineage-specific chimerism analysis was 100% and 100%, respectively. The cumulative incidence of grade 2-4 acute GvHD at day 100 was 25%. CMV reactivation or disease requiring therapy was detected in 11 (26%) patients (Table 2 ). Among patients receiving myeloablative conditioning (Flu/Bu/CY), 40% (n = 6) developed CMV reactivation. CMV tissue invasive disease (CMV hepatitis = 1; CMV duodenitis = 1) occurred in two patients who underwent myeloablative conditioning. Adenoviral reactivation was infrequent and there were no cases of EBV reactivation (Table 2) . BK virus reactivation was frequent in our patient cohort (N = 15; 35%). Four patients (17%) receiving Flu/CY/TBI conditioning developed mild, grade 1 BK virus-associated cystitis. Grade 2 or higher BK virus-associated hemorrhagic cystitis was present in a total of 11 (26%) patients. Grade 2-4 BK virus-associated hemorrhagic cystitis was significantly more frequent in patients receiving myeloablative conditioning (n = 7, 47%) compared with patients receiving RIC (n = 4, 14.3%; P = 0.02). Six out of the 7 patients in the myeloablative cohort with grade 2-4 hemorrhagic cystitis, had severe (grade 3-4) cystitis. HHV-6 reactivation was diagnosed in 13 (30%) patients post transplant. Median time to HHV-6 reactivation was 29 (range 17-62) days. In the myeloablative group, 5 (33%) patients developed HHV-6 reactivation. Two of these patients had HHV-6 disease causing secondary graft failure (n = 1) and encephalitis (n = 1). One patient who received RIC developed HHV-6-associated seizures. Viral respiratory infections were diagnosed in~20% of patients in each conditioning regimen (Table 2 ). In four patients experiencing non-relapse mortality (that is, death without evidence of disease relapse or progression) in our cohort, parainfluenza pneumonia was a contributing cause of death in one patient.
Our analysis is limited by its retrospective nature and small sample size. With these limitations in mind, we report here a few important observations. CMV reactivations appear more frequent in patients receiving myeloablative Flu/Bu/CY (40%) compared with RIC (11%), but this difference was not statistically significant. Of note CMV organ infections (despite the use of preemptive therapy) were only seen following myeloablative conditioning. Severe BK virus-associated hemorrhagic cystitis was significantly more common in patients receiving Flu/Bu/CY myeloablative conditioning compared with patients receiving non-myeloablative conditioning with Flu/CY/TBI. BK virusassociated hemorrhagic cystitis was a major infectious burden in our patient cohort. Solomon et al. 8 have also shown high rates of BK virus-associated cystitis, affecting 75% of patients with severe hemorrhagic cystitis (requiring hospital admission for bladder irrigation and/or pain management) in 35% of patients receiving myeloablative conditioning with Flu/Bu/CY. The high rates of severe BK virus-associated hemorrhagic cystitis following Flu/Bu/CY conditioning might be due to myeloablative doses of busulfan. The rates of BK virusassociated hemorrhagic cystitis appear to be lower in busulfanfree myeloablative conditioning regimens used in haplo-HCT. For example, after myeloablative conditioning with fludarabine and 12 Gy TBI severe BK virus-associated hemorrhagic cystitis was seen in only 7% of the patients. 9 It is also plausible that CY in the Flu/Bu/CY conditioning contributed to the high rates of BK virus-associated hemorrhagic cystitis in our study.
The high incidence of viral reactivations and infections in the early post-transplant period poses a significant challenge in haplo-HCT. In contrast to frequent viral reactivations/infections following haplo-HCT in the current analysis, the rates of similar complications following matched adult donor HCT using standard tacrolimus-/methotrexate-based GvHD prophylaxis in our center are substantially lower (rates of CMV reactivation, BK-viral hemorrhagic cystitis and adenoviral reactivation in a contemporaneous trial using HLA-matched adult donors in our center were 15.3%, 6.3% and 1.2%, respectively; NCT01665677; manuscript in preparation). A handful of previous studies have also reported frequent CMV reactivations and BK virus-associated cystitis in the T-cell replete haplo-HCT platform. 4, 6, 10 The majority of viral infections/reactivations in our study occurred in the first 30 days post transplant. These infections and their treatment in the immediate post-engraftment period can be associated with significant morbidity (for example, renal toxicity, bone marrow suppression and graft failure). Viral infections continue to be a major cause of transplant-related morbidity in haplo-HCT using PT-Cy platform. Immunotherapeutic strategies to improve virusspecific immunity like donor lymphocyte infusion or virus-specific T cells are possible treatment options in severe infections. 10, 11 In conclusion, our study shows that viral infections in the posttransplant period of haplo-HCT remains a significant challenge and contributes to cause significant morbidity in this patient population. The risk of viral complications appears to be higher following conditioning regimens containing myeloablative doses of busulfan. Abbreviations: Bu = busulfan; CY = cyclophosphamide; Flu = fludarabine; HL = Hodgkin's lymphoma; Mel = melphalan; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma. Respiratory syncytial virus (n = 1), parainfluenza (n = 1). f Rhinovirus (n = 2). g Parainfluenza (n = 1), influenza B (n = 1). h Rhinovirus (n = 1).
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